These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36788188)

  • 1. Tumor Burden Monitoring with Circulating Tumor DNA During Treatment in Patients with Esophageal Squamous Cell Carcinoma.
    Morimoto Y; Matsuda S; Kawakubo H; Nakamura K; Kobayashi R; Hisaoka K; Okui J; Takeuchi M; Aimono E; Fukuda K; Nakamura R; Saya H; Nishihara H; Kitagawa Y
    Ann Surg Oncol; 2023 Jun; 30(6):3747-3756. PubMed ID: 36788188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
    Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
    JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma.
    Wang X; Yu N; Cheng G; Zhang T; Wang J; Deng L; Li J; Zhao X; Xu Y; Yang P; Bai N; Li Y; Bi N
    Clin Transl Med; 2022 Nov; 12(11):e1116. PubMed ID: 36437506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.
    Ueda M; Iguchi T; Masuda T; Nakahara Y; Hirata H; Uchi R; Niida A; Momose K; Sakimura S; Chiba K; Eguchi H; Ito S; Sugimachi K; Yamasaki M; Suzuki Y; Miyano S; Doki Y; Mori M; Mimori K
    Oncotarget; 2016 Sep; 7(38):62280-62291. PubMed ID: 27556701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease guided radical chemoradiotherapy combined with immunotherapy after neoadjuvant immunochemotherapy followed by adjuvant immunotherapy for esophageal squamous cell cancer (ECMRD-001): a study protocol for a prospective cohort study.
    Wang H; Zhang X; Zhao X; Song C; Deng W; Shen W
    Front Immunol; 2023; 14():1330928. PubMed ID: 38274807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive diagnosis and monitoring of mutations by deep sequencing of circulating tumor DNA in esophageal squamous cell carcinoma.
    Luo H; Li H; Hu Z; Wu H; Liu C; Li Y; Zhang X; Lin P; Hou Q; Ding G; Wang Y; Li S; Wei D; Qiu F; Li Y; Wu S
    Biochem Biophys Res Commun; 2016 Mar; 471(4):596-602. PubMed ID: 26876573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted sequencing of circulating cell-free DNA in stage II-III resectable oesophageal squamous cell carcinoma patients.
    Meng P; Wei J; Geng Y; Chen S; Terpstra MM; Huang Q; Zhang Q; Su Z; Yu W; Su M; Kok K; van den Berg A; Gu J
    BMC Cancer; 2019 Aug; 19(1):818. PubMed ID: 31429737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Barcode Sequencing for Highly Sensitive Detection of Circulating Tumor DNA in Patients with Esophageal Squamous Cell Carcinoma.
    Hagi T; Kurokawa Y; Takahashi T; Saito T; Yamashita K; Tanaka K; Makino T; Yamasaki M; Nakajima K; Mori M; Doki Y
    Oncology; 2020; 98(4):222-229. PubMed ID: 31846968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer.
    Azad TD; Chaudhuri AA; Fang P; Qiao Y; Esfahani MS; Chabon JJ; Hamilton EG; Yang YD; Lovejoy A; Newman AM; Kurtz DM; Jin M; Schroers-Martin J; Stehr H; Liu CL; Hui AB; Patel V; Maru D; Lin SH; Alizadeh AA; Diehn M
    Gastroenterology; 2020 Feb; 158(3):494-505.e6. PubMed ID: 31711920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
    Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
    JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy.
    Kim EJ; Im HS; Lee J; Cho EH; Kim YH; Kim HR; Kim JH; Park SR
    Curr Probl Cancer; 2021 Jun; 45(3):100685. PubMed ID: 33342577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.
    Honoré N; van Marcke C; Galot R; Helaers R; Ambroise J; van Maanen A; Mendola A; Dahou H; Marbaix E; Van Eeckhout P; Longton E; Magremanne M; Schmitz S; Limaye N; Machiels JP
    Ann Oncol; 2023 Dec; 34(12):1175-1186. PubMed ID: 37879442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
    Magbanua MJM; Swigart LB; Wu HT; Hirst GL; Yau C; Wolf DM; Tin A; Salari R; Shchegrova S; Pawar H; Delson AL; DeMichele A; Liu MC; Chien AJ; Tripathy D; Asare S; Lin CJ; Billings P; Aleshin A; Sethi H; Louie M; Zimmermann B; Esserman LJ; van 't Veer LJ
    Ann Oncol; 2021 Feb; 32(2):229-239. PubMed ID: 33232761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes.
    Tian D; Zhang L; Wang Y; Chen L; Zhang KP; Zhou Y; Wen HY; Fu MY
    Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30247659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study.
    Zhou J; Wang C; Lin G; Xiao Y; Jia W; Xiao G; Liu Q; Wu B; Wu A; Qiu H; Zhang F; Hu K; Xue H; Shen Z; Wang Z; Han J; Niu B; Xu Y; Yu Z; Yang L
    Clin Cancer Res; 2021 Jan; 27(1):301-310. PubMed ID: 33046514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma.
    Tamura D; Abe M; Hiraki H; Sasaki N; Yashima-Abo A; Ikarashi D; Kato R; Kato Y; Maekawa S; Kanehira M; Takata R; Maejima K; Sasagawa S; Fujita M; Suzuki Y; Nakagawa H; Iwaya T; Nishizuka SS; Obara W
    Cancer Sci; 2024 Feb; 115(2):529-539. PubMed ID: 38083992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma.
    Cabalag CS; Yates M; Corrales MB; Yeh P; Wong SQ; Zhang BZ; Fujihara KM; Chong L; Hii MW; Dawson SJ; Phillips WA; Duong CP; Clemons NJ
    Ann Surg; 2022 Aug; 276(2):e120-e126. PubMed ID: 35737908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
    Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
    JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment.
    Matsuda S; Takeuchi H; Fukuda K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
    Dis Esophagus; 2014; 27(7):654-61. PubMed ID: 23980622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.